Lupin Shares Climb 2% Led By Strong Q2 Revenue, Operating Income
Pharma major Lupin Ltd.’s share price advanced in trade on Friday after the company reported strong financials for the quarter ended September. The company’s share price was up 1.92% at Rs 1,993 apiece, within an hour of market open.
Lupin saw a 73.34% annual increase in net profit to Rs 1,478 crore for the quarter ended September 2025, as compared to Rs 852.6 crore in the same period last year. Revenue from operations rose 24.2% in the same period to Rs 7,047.5 crore, as compared to Rs 5,672.7 crore last year.
Key Highlights Of Lupin’s Q2 Results
- Earnings before interest, tax, depreciation, and amortisation rose 74.7% to Rs 2,341.7 crore, against Rs 1,340.5 crore a year ago.
- The company’s margin stood at 33.2%, up from 23.6% in the corresponding quarter of the previous year.
- Nilesh Gupta, Managing Director of Lupin, said, ‘We are delighted to present one of our strongest performances ever in this second quarter of FY26.’
For investors looking to invest in the pharma sector, Lupin’s strong Q2 performance is a positive sign. The company’s robust growth in revenues and EBITDA, led by strong performance across the board, in the US, emerging markets, other developed markets, and in India, supported by higher operational efficiencies and sustained investments, makes it an attractive option.
Impact On Indian Stock Markets
The Indian stock markets, including the Nifty 50 Index and the Sensex Index, have been volatile in recent times. However, with strong Q2 results from major companies like Lupin, investor sentiment is likely to remain positive.
For more information on Indian stock market news and updates on the Nifty and Sensex levels, please visit our website.
Investment Strategies For Indian Investors
Indian investors looking to invest in the stock market can consider a long-term approach, focusing on fundamental analysis and technical analysis to make informed investment decisions.
Additionally, investors can consider diversifying their portfolios by investing in mutual funds or exchange-traded funds, which can provide exposure to a broad range of assets and reduce risk.
Conclusion
In conclusion, Lupin’s strong Q2 performance is a positive sign for the Indian pharma sector and the overall stock market. With a long-term approach and a well-diversified portfolio, Indian investors can navigate the volatility of the stock market and achieve their investment goals.